mTOR signaling pathway in cancer targets photodynamic therapy in vitro

Sandra M. Ayuk; Heidi Abrahamse

doi:10.3390/cells8050431

mTOR signaling pathway in cancer targets photodynamic therapy in vitro

Sandra M. Ayuk, Heidi Abrahamse

Laser Research Centre

University of Johannesburg

Research output: Contribution to journal › Review article › peer-review

20 Citations (Scopus)

Abstract

The Mechanistic or Mammalian Target of Rapamycin (mTOR) is a major signaling pathway in eukaryotic cells belonging to the P13K-related kinase family of the serine/threonine protein kinase. It has been established that mTOR plays a central role in cellular processes and implicated in various cancers, diabetes, and in the aging process with very poor prognosis. Inhibition of the mTOR pathway in the cells may improve the therapeutic index in cancer treatment. Photodynamic therapy (PDT) has been established to selectively eradicate neoplasia at clearly delineated malignant lesions. This review highlights recent advances in understanding the role or regulation of mTOR in cancer therapy. It also discusses how mTOR currently contributes to cancer as well as future perspectives on targeting mTOR therapeutically in cancer in vitro.

Original language	English
Article number	431
Journal	Cells
Volume	8
Issue number	5
DOIs	https://doi.org/10.3390/cells8050431
Publication status	Published - May 2019

Keywords

Cancers
Inhibitors
MTOR
Photodynamic therapy

ASJC Scopus subject areas

General Biochemistry,Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cells8050431

Cite this

@article{b4f15a59b5f04af5b8bc69217c9d6e5e,

title = "mTOR signaling pathway in cancer targets photodynamic therapy in vitro",

abstract = "The Mechanistic or Mammalian Target of Rapamycin (mTOR) is a major signaling pathway in eukaryotic cells belonging to the P13K-related kinase family of the serine/threonine protein kinase. It has been established that mTOR plays a central role in cellular processes and implicated in various cancers, diabetes, and in the aging process with very poor prognosis. Inhibition of the mTOR pathway in the cells may improve the therapeutic index in cancer treatment. Photodynamic therapy (PDT) has been established to selectively eradicate neoplasia at clearly delineated malignant lesions. This review highlights recent advances in understanding the role or regulation of mTOR in cancer therapy. It also discusses how mTOR currently contributes to cancer as well as future perspectives on targeting mTOR therapeutically in cancer in vitro.",

keywords = "Cancers, Inhibitors, MTOR, Photodynamic therapy",

author = "Ayuk, {Sandra M.} and Heidi Abrahamse",

note = "Publisher Copyright: {\textcopyright} 2019 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2019",

month = may,

doi = "10.3390/cells8050431",

language = "English",

volume = "8",

journal = "Cells",

issn = "2073-4409",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "5",

}

TY - JOUR

T1 - mTOR signaling pathway in cancer targets photodynamic therapy in vitro

AU - Ayuk, Sandra M.

AU - Abrahamse, Heidi

PY - 2019/5

Y1 - 2019/5

N2 - The Mechanistic or Mammalian Target of Rapamycin (mTOR) is a major signaling pathway in eukaryotic cells belonging to the P13K-related kinase family of the serine/threonine protein kinase. It has been established that mTOR plays a central role in cellular processes and implicated in various cancers, diabetes, and in the aging process with very poor prognosis. Inhibition of the mTOR pathway in the cells may improve the therapeutic index in cancer treatment. Photodynamic therapy (PDT) has been established to selectively eradicate neoplasia at clearly delineated malignant lesions. This review highlights recent advances in understanding the role or regulation of mTOR in cancer therapy. It also discusses how mTOR currently contributes to cancer as well as future perspectives on targeting mTOR therapeutically in cancer in vitro.

AB - The Mechanistic or Mammalian Target of Rapamycin (mTOR) is a major signaling pathway in eukaryotic cells belonging to the P13K-related kinase family of the serine/threonine protein kinase. It has been established that mTOR plays a central role in cellular processes and implicated in various cancers, diabetes, and in the aging process with very poor prognosis. Inhibition of the mTOR pathway in the cells may improve the therapeutic index in cancer treatment. Photodynamic therapy (PDT) has been established to selectively eradicate neoplasia at clearly delineated malignant lesions. This review highlights recent advances in understanding the role or regulation of mTOR in cancer therapy. It also discusses how mTOR currently contributes to cancer as well as future perspectives on targeting mTOR therapeutically in cancer in vitro.

KW - Cancers

KW - Inhibitors

KW - MTOR

KW - Photodynamic therapy

UR - http://www.scopus.com/inward/record.url?scp=85070582172&partnerID=8YFLogxK

U2 - 10.3390/cells8050431

DO - 10.3390/cells8050431

M3 - Review article

AN - SCOPUS:85070582172

SN - 2073-4409

VL - 8

JO - Cells

JF - Cells

IS - 5

M1 - 431

ER -

mTOR signaling pathway in cancer targets photodynamic therapy in vitro

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this